Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT05206734 Active, not recruiting - Schizophrenia Clinical Trials

Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Start date: January 5, 2022
Phase:
Study type: Observational

This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the risk of mental health conditions in children, adolescents and young adults with Inflammatory Bowel Disease, compared to those without Inflammatory Bowel Disease. The study will also compare the impacts on quality-of-life outcomes and use of healthcare services between people with Inflammatory Bowel Disease with and without mental health conditions.

NCT ID: NCT05206292 Not yet recruiting - Schizophrenia Clinical Trials

Estimating Prevalence of Inherited Disorders of Sulfur Amino Acids Metabolism in Patients With Psychotic Disorders.

PsyNIT
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Screening for sulfur amino acid metabolism pathologies using a sulfitest in adult patients with psychotic disorder.

NCT ID: NCT05204407 Not yet recruiting - Schizophrenia Clinical Trials

Luteolin for the Treatment of People With Schizophrenia

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

Luteolin is a natural product found in foods such as celery, green pepper, parsley, and chamomile tea. It has been found to have anti-cancer, anti-oxidant, and anti-inflammatory properties. The purpose of this study is to determine if luteolin helps improve symptoms of schizophrenia.

NCT ID: NCT05200962 Not yet recruiting - Schizophrenia Clinical Trials

Electrical Brain Stimulation for Cognitive Impairment in Schizophrenia: a tDCS-fMRI Study

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the mechanism of action of transcranial electrical brain stimulation over the dorsolateral prefrontal cortex for cognitive impairment in schizophrenia. To do so the effect of a novel stimulation protocol will be investigated in the fMRI scanner.

NCT ID: NCT05193578 Recruiting - Schizophrenia Clinical Trials

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

HISTORI
Start date: January 12, 2022
Phase: Phase 2
Study type: Interventional

To investigate whether the Glucagon Like Peptide 1 (GLP-1) Semaglutide (1.34 mg/ml) has preventive effect compared to placebo in the development of diabetes and Metabolic Syndrome in people with pre-diabetes, overweight and schizophrenia, who receive antipsychotic treatment. Furthermore to investigate for an effect of Semaglutide compared to placebo on psychotic symptoms and quality of life in people with schizophrenia, prediabetes and overweight.

NCT ID: NCT05192304 Not yet recruiting - Schizophrenia Clinical Trials

Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia

TPN672
Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase Ib clinical study of TPN672 maleate in patients with schizophrenia

NCT ID: NCT05184335 Not yet recruiting - Schizophrenia Clinical Trials

Safety and Efficacy of Brilaroxazine (RP5063) in Patients With an Acute Exacerbation of Schizophrenia, Then 52-Week Open-label Extension

RECOVER
Start date: January 24, 2022
Phase: Phase 3
Study type: Interventional

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily. The aim of this study is to also assess the long-term tolerability of these tablets over a period of 52 weeks.

NCT ID: NCT05182476 Recruiting - Schizophrenia Clinical Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia

ERUDITE
Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in subjects with schizophrenia.

NCT ID: NCT05179525 Completed - Schizophrenia Clinical Trials

Comparative Bioavailability of Risperidone.

Start date: March 9, 2021
Phase: Phase 1
Study type: Interventional

This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).

NCT ID: NCT05174533 Not yet recruiting - Schizophrenia Clinical Trials

Prevalence of Cardiovascular Disorders in Patients Aged 40 and More With Schizophrenia

SCHIZO-CV
Start date: January 1, 2022
Phase:
Study type: Observational

Schizophrenia is a psychiatric disorder, affecting 600,000 patients in France. Patients with schizophrenia have life expectancy decrease from 10 to 20 years because of cardiovascular death. Cardiovascular risk factors are numerous: inadequate diet, smoking, alcohol consumption, diabetes, obesity. Primary prevention of cardiovascular risk in patients suffering from schizophrenia is difficult because of understaff in general practitioners and psychiatrists.